Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats
- PMID: 29122691
- PMCID: PMC5835407
- DOI: 10.1016/j.brainresbull.2017.11.002
Sexually diergic hypothalamic-pituitary-adrenal axis responses to selective and non-selective muscarinic antagonists prior to cholinergic stimulation by physostigmine in rats
Abstract
Central cholinergic systems regulate the hypothalamic-pituitary-adrenal (HPA) axis differentially in males and females (sexual diergism). We previously investigated the role of muscarinic receptors in this regulation by administering physostigmine (PHYSO), an acetylcholinesterase inhibitor, to male and female rats pretreated with scopolamine (SCOP), a nonselective muscarinic antagonist. SCOP pretreatment enhanced adrenocorticotropic hormone (ACTH) and corticosterone (CORT) responses in both sexes, but males had greater ACTH responses while females had greater CORT responses. In the present study, we further explored the role of muscarinic receptor subtypes in HPA axis regulation by administering PHYSO to male and female rats following SCOP or various doses of either the M1 or the M2 selective muscarinic receptor antagonists, pirenzepine (PIREN) or methoctramine (METHO). Blood was sampled before and at multiple times after PHYSO. ACTH and CORT were determined by highly specific immunoassays. M1 antagonism by PIREN prior to PHYSO resulted in sustained, dose-dependent increases in ACTH and CORT: ACTH responses were similar in both sexes, and CORT responses were greater in females. M2 antagonism by METHO prior to PHYSO resulted in overall decreases in ACTH and CORT: ACTH and CORT responses were higher in females but lower in both sexes than the hormone responses following PIREN or SCOP pretreatment. Area under the curve analyses supported these findings. These results suggest that specific muscarinic receptor subtypes differentially influence the HPA axis in a sexually diergic manner.
Keywords: Cholinergic; Methoctramine; Muscarinic; Pirenzepine; Scopolamine; Sexual diergism.
Copyright © 2017 Elsevier Inc. All rights reserved.
Conflict of interest statement
None.
Figures








Similar articles
-
Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism.Brain Res Bull. 2001 Jan 1;54(1):101-13. doi: 10.1016/s0361-9230(00)00449-4. Brain Res Bull. 2001. PMID: 11226719
-
Male-female differences in rat hypothalamic-pituitary-adrenal axis responses to nicotine stimulation.Brain Res Bull. 2001 Apr;54(6):681-8. doi: 10.1016/s0361-9230(01)00488-9. Brain Res Bull. 2001. PMID: 11403996
-
Estrous cycle influences on sexual diergism of HPA axis responses to cholinergic stimulation in rats.Brain Res Bull. 2002 Nov 30;59(3):217-25. doi: 10.1016/s0361-9230(02)00868-7. Brain Res Bull. 2002. PMID: 12431752
-
Functional sex differences ('sexual diergism') of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: a selective review.Brain Res Brain Res Rev. 1999 Aug;30(2):135-52. doi: 10.1016/s0165-0173(99)00011-9. Brain Res Brain Res Rev. 1999. PMID: 10525171 Review.
-
Role of gonadal hormones in programming developmental changes in thymopoietic efficiency and sexual diergism in thymopoiesis.Immunol Res. 2012 Apr;52(1-2):7-19. doi: 10.1007/s12026-012-8278-6. Immunol Res. 2012. PMID: 22407539 Review.
Cited by
-
Influence of Anticholinesterase Drugs on Activity and Properties of Na+,K+-ATPase in Rat Erythrocytes under Stress Caused by Intense Physical Exercise.Bull Exp Biol Med. 2024 Aug;177(4):427-430. doi: 10.1007/s10517-024-06202-z. Epub 2024 Sep 11. Bull Exp Biol Med. 2024. PMID: 39259465
-
Neuroimmunology: What Role for Autoimmunity, Neuroinflammation, and Small Fiber Neuropathy in Fibromyalgia, Chronic Fatigue Syndrome, and Adverse Events after Human Papillomavirus Vaccination?Int J Mol Sci. 2019 Oct 18;20(20):5164. doi: 10.3390/ijms20205164. Int J Mol Sci. 2019. PMID: 31635218 Free PMC article. Review.
-
Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease.Curr Alzheimer Res. 2024;21(1):50-68. doi: 10.2174/0115672050306008240321034006. Curr Alzheimer Res. 2024. PMID: 38529600 Review.
References
-
- Abrams P, Andersson K-EE, Buccafusco JJ, Chapple C, Groat WC, de Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–78. - PMC - PubMed
-
- Aramakis VB, Bandrowski AE, Ashe JH. Role of muscarinic receptors, G-proteins, and intracellular messengers in muscarinic modulation of NMDA receptor-mediated synaptic transmission. Synapse. 1999;32:262–75. - PubMed
-
- Assenmacher I, Szafarczyk A, Alonso G, Ixart G, Barbanel G. Physiology of neural pathways affecting CRH secretion. Ann N Y Acad Sci. 1987;512:149–61. - PubMed
-
- Aura J, Sirviö J, Riekkinen P. Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. Eur J Pharmacol. 1997;333:129–34. - PubMed
-
- Avissar S, Egozi Y, Sokolovsky M. Studies on muscarinic receptors in mouse and rat hypothalamus: a comparison of sex and cyclical differences. Neuroendocrinology. 1981a;32:295–302. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources